James Crutcher, MD
Orthopaedic Surgery · Seattle, WANPI 1881663292
Payments from drug & device makers
Across 725 payments — averaging $4766.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$3.5M
- Medacta USA, Inc.$1K
- Smith+Nephew$516
- Zimmer Biomet$442
- Avanos Medical$441
- Orthalign Inc$351
- plus $804 from 6 others
What the payments were for
- Royalty or licence$2,709,10678%
- Consulting fees$591,81917%
- Travel & lodging$138,4744%
- Food & beverage$16,4420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 694 | $3,452,251 |
| Medacta USA, Inc. | 6 | $1,037 |
| Smith+Nephew | 4 | $516 |
| Zimmer Biomet | 4 | $442 |
| Avanos Medical | 4 | $441 |
| Orthalign Inc | 3 | $351 |
| Davol Inc. | 1 | $267 |
| Heron Therapeutics, Inc. | 4 | $210 |
| Omnilife Science, Inc | 1 | $173 |
| Johnson & Johnson(2 entities) | 2 | $99 |
| Orthosensor Inc. | 1 | $35 |
| Medical Device Business Services, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRIATHLON$2,828,998
- MAKO$655,063
- INSIGNIA$86,613
- RESTORATION$25,979
- NEW PRODUCT DEVELOPMENT$20,305
- ACCOLADE$19,942
- TRIDENT$19,506
- TRITANIUM$6,038
- RESTORIS$3,450
- GMRS$2,588
- AEQUALIS$2,300
- DURACON$1,150
- GMK SPHERE$880
- EVOS$839
- SURPASS EVOLVE$708
- ON-Q* PUMP AND ACCESSORIES$367
- ORTHALIGN PLUS$255
- Apollo Knee (FKA OMNIBotics 3.0)$173
- Persona$157
- G7$145
How this compares
$3,455,841 in reported general payments places this provider in the 95th percentile of 495 orthopaedic surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 82 | $278 |
| Amoxicillin | 109 | $172 |
| Tramadol Hcl | 11 | $69 |
| Clindamycin Hcl | 31 | $57 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Seattle
- James PritchettSeattle$6.4M
- Jeffrey RohSeattle$4.7M
- Keith MayoSeattle$3.1M
- Matthew SaltzmanSeattle$1.8M
- Burt YaszaySeattle$1.5M
- Sean ToomeySeattle$1.3M
- Robert HartSeattle$942K
- Daniel SchwartzSeattle$508K
- Michael BrageSeattle$507K
- Grant GarciaSeattle$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.